Company news

Scholar Rock Holding Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Scholar Rock Announces Issuance of U.S. Patent Protecting Add-On or Combination Therapy with a Myostatin Inhibitor for the Treatment of Spinal Muscular Atrophy

March 16, 2021

Scholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in Spinal Muscular Atrophy at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

March 14, 2021

Scholar Rock Reports Full Year 2020 Financial Results and Highlights Business Progress

March 8, 2021

Scholar Rock Announces Senior Management Promotions

February 3, 2021

Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit

January 26, 2021

Scholar Rock Provides Corporate Update and Highlights Priorities for 2021

January 10, 2021

Scholar Rock to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 3, 2021

Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress

November 8, 2020

Scholar Rock Announces Closing of Public Offering of Common Stock and Prefunded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

November 1, 2020

Scholar Rock Announces Pricing of Public Offering of Common Stock and Prefunded Warrants

October 27, 2020

Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy

October 26, 2020

Scholar Rock Secures $50 million Debt Facility with Silicon Valley Bank and Oxford Finance

October 18, 2020

Scholar Rock Presents Data for SRK-015 at the World Muscle Society 2020 Virtual Congress

September 29, 2020

Scholar Rock Announces First Patient Dosed in Part A2 of DRAGON Phase 1 Proof-of-Concept Trial of SRK-181 to Overcome Primary Resistance to Anti-PD-(L)1 Therapy

September 8, 2020

Scholar Rock Announces Issuance of U.S. Patent Providing Composition of Matter Protection for SRK-015

August 26, 2020

Scholar Rock Announces that SRK-015 has Received Rare Pediatric Disease Designation from U.S. FDA for the Treatment of Spinal Muscular Atrophy

August 12, 2020

Scholar Rock Reports Second Quarter 2020 Financial Results and Highlights Business Progress

August 6, 2020

Scholar Rock to Present at the 2020 Wedbush PacGrow Healthcare Conference

August 4, 2020

Scholar Rock to Announce Second Quarter 2020 Financial Results and Introduce Newest Members of Management August 7, 2020

August 2, 2020

Scholar Rock Appoints Edward (Ted) Myles as Chief Financial Officer and Head of Business Operations

July 15, 2020

Scholar Rock Appoints Tony Kingsley as President and CEO

July 13, 2020

Scholar Rock to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

June 15, 2020

Scholar Rock Presents Clinical and Preclinical Data for SRK-015 at the 2020 Virtual Cure SMA Research and Clinical Care Meeting

June 11, 2020

Scholar Rock to Present at the Jefferies Virtual Global Healthcare Conference

May 26, 2020

Scholar Rock Appoints Tony Kingsley to Its Board of Directors

May 20, 2020

Scholar Rock Presents Baseline Demographics Data from the SRK-015 TOPAZ Trial at the American Academy of Neurology Conference

May 17, 2020

Scholar Rock Reports First Quarter 2020 Financial Results and Highlights Business Progress

May 6, 2020

Scholar Rock Announces Initiation of Patient Dosing in Phase 1 Proof-of-Concept Immuno-Oncology Trial of SRK-181 to Overcome Primary Resistance to Anti-PD-(L)1 Therapy

May 4, 2020

Scholar Rock Announces Issuance of U.S. Patent Broadly Relevant to Antibodies that Modulate TGFβ Activation

April 8, 2020

Scholar Rock Reports Full Year 2019 Financial Results and Highlights Business Progress

March 11, 2020

Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences

January 8, 2020

Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy

November 18, 2019

Scholar Rock Reports Third Quarter 2019 Financial Results and Highlights Business Progress

November 11, 2019

← Newer news releases

Calls

The 5 newest of 11 calls. Every call is listed under its year.

Decks

The 5 newest of 43 decks. Every deck is listed under its year.